Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Novartis
Hoffmann-La Roche
Nagoya City University
AstraZeneca
Hoffmann-La Roche
Eli Lilly and Company
Gustave Roussy, Cancer Campus, Grand Paris
Forward Pharmaceuticals Co., Ltd.
Stemline Therapeutics, Inc.
Avenzo Therapeutics, Inc.
Jonsson Comprehensive Cancer Center